Mohamed Sara A, Shalaby Shahinaz M, Abdelaziz Mohamed, Brakta Soumia, Hill William D, Ismail Nahed, Al-Hendy Ayman
1 Division of Translation Research, Department of Obstetrics and Gynecology, Medical College of Georgia Augusta University, Augusta, GA, USA.
2 Department of Obstetrics and Gynecology, Mansoura Faculty of Medicine, Mansoura University Hospital, Mansoura, Egypt.
Reprod Sci. 2018 Jan;25(1):51-63. doi: 10.1177/1933719117699705. Epub 2017 May 1.
Chemotherapy is the most commonly used modality to treat human cancers; however, in many cases it causes irreversible ovarian failure. In this work, we plan to evaluate the restorative function of human bone marrow mesenchymal stem cells (BMSCs) in a chemotherapy-induced ovarian failure mouse model.
Acclimatized 4 to 6 week-old female mice (C57BL/6) were assigned randomly to a vehicle-treated control group (group 1), chemotherapy-treated group followed by vehicle alone (group 2), or chemotherapy-treated group followed by stem cell intraovarian injection (group 3). Outcomes were evaluated using immunohistochemistry (IHC), serum hormonal assays, and estrous cycle monitoring and breeding potential.
Post BMSCs administration, group 3 promptly showed detectable vaginal smears with estrogenic changes. Increase in total body weight, ovarian weight, and weight of estrogen-responsive organs (uterus and liver) was observed at 2 weeks and continued to end of the experiment. Hematoxylin and Eosin histological evaluation of the ovaries demonstrated a higher mean follicle count in group 3 than in group 2. Group 3 had lower follicle-stimulating hormone (FSH) levels ( P = .03) and higher anti-Müllerian hormone serum (AMH) levels ( P = .0005) than group 2. The IHC analysis demonstrated higher expression of AMH, FSH receptor, inhibin A, and inhibin B in growing follicles of group 3 versus group 2. Tracking studies demonstrated that human BMSCs evenly repopulated the growing follicles in treated ovaries. Importantly, breeding data showed significant increases in the pregnancies numbers, 2 pregnancies in group 1 and 12 in group 3 ( P = .02).
Intraovarian administered BMSCs are able to restore ovarian hormone production and reactivate folliculogenesis in chemotherapy-induced ovarian failure mouse model.
化疗是治疗人类癌症最常用的方法;然而,在许多情况下,它会导致不可逆的卵巢功能衰竭。在本研究中,我们计划在化疗诱导的卵巢功能衰竭小鼠模型中评估人骨髓间充质干细胞(BMSCs)的恢复功能。
将适应环境4至6周龄的雌性小鼠(C57BL/6)随机分为溶剂处理对照组(第1组)、化疗后仅给予溶剂的治疗组(第2组)或化疗后进行干细胞卵巢内注射的治疗组(第3组)。使用免疫组织化学(IHC)、血清激素测定、发情周期监测和繁殖潜力来评估结果。
给予BMSCs后,第3组迅速出现具有雌激素变化的可检测阴道涂片。在2周时观察到总体重、卵巢重量以及雌激素反应器官(子宫和肝脏)重量增加,并持续到实验结束。卵巢苏木精和伊红组织学评估显示,第3组的平均卵泡计数高于第2组。第3组的促卵泡激素(FSH)水平低于第2组(P = 0.03),抗苗勒管激素血清(AMH)水平高于第2组(P = 0.0005)。免疫组织化学分析表明,与第2组相比,第3组生长卵泡中AMH、FSH受体、抑制素A和抑制素B的表达更高。追踪研究表明,人BMSCs均匀地重新填充了治疗卵巢中的生长卵泡。重要的是,繁殖数据显示妊娠数量显著增加,第1组有2次妊娠,第3组有12次妊娠(P = 0.02)。
在化疗诱导的卵巢功能衰竭小鼠模型中,卵巢内注射BMSCs能够恢复卵巢激素分泌并重新激活卵泡发生。